环泊酚与不同麻醉药联合应用的临床研究进展

Clinical Research Progress on the Combined Application of Ciprofol with Different Anesthetic Agents

摘要: 环泊酚是我国自主研发的新型2,6-二取代苯酚类静脉麻醉药，为丙泊酚的结构优化衍生物。该药具备起效迅速、苏醒迅速、血流动力学稳定性良好及不良反应发生率低等药理优势，目前已广泛用于围手术期麻醉诱导与维持、门诊短小手术及镇静操作。鉴于单一麻醉药物在复杂围手术期管理中常面临镇痛镇静覆盖不足、循环功能抑制、苏醒延迟及术后躁动等问题。多药联合麻醉则通过不同药物间的靶点互补与机制协同，有助于实现麻醉深度的精准调控、应激反应的有效抑制以及围术期安全的整体优化。本综述系统梳理环泊酚的药理与生理机制，重点总结其与阿片类药物、依托咪酯、艾司氯胺酮、七氟烷及右美托咪定联合应用的临床研究进展，以期为围术期个体化复合麻醉方案的优化选择提供循证支持，也为新型静脉麻醉药的联合用药研究拓展思路。

Abstract: Ciclopol is a new type of 2,6-disubstituted phenol intravenous anesthetics independently developed in China. It is a structurally optimized derivative of propofol. It has the pharmacological advantages of rapid onset, rapid recovery, good hemodynamic stability and low incidence of adverse reactions. It has been widely used in perioperative anesthesia induction and maintenance, outpatient short surgery and sedation. In view of the fact that single anesthetics often face problems such as insufficient analgesic and sedative coverage, circulatory function inhibition, delayed recovery, and postoperative agitation in complex perioperative management. Multi-drug combined anesthesia helps to achieve precise regulation of anesthesia depth, effective inhibition of stress response and overall optimization of perioperative safety through target complementarity and mechanism synergy between different drugs. This review systematically summarizes the pharmacological and physiological mechanisms of cipol, and focuses on the clinical research progress of its combined application with opioids, etomidate, esketamine, sevoflurane and dexmedetomidine, in order to provide evidence-based support for the optimization of perioperative individualized compound anesthesia, and also expand the ideas for the research of new intravenous anesthetics.